Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients

Diffuse large B-cell lymphoma is a serious cancer that can affect many parts of the body. For people who have never had treatment before, a new analysis of data shows that the drug zanubrutinib works very well. In this review, researchers looked at results from 1,346 patients. They found that 95 percent of those who had not received prior therapy saw their disease shrink or disappear. Even older patients saw an 90.7 percent response rate. This is important because many people with this cancer are elderly. The drug also worked well for those whose disease had spread to areas outside the lymph nodes. For people who had already tried other treatments, the drug helped 67.5 percent of patients. The follow-up period lasted an average of 31.2 months. During this time, the disease did not grow back in many of the untreated patients. Survival time for these patients had not been reached yet. For those with relapsed disease, survival lasted 21.8 months. The review did not report specific safety data or side effects in the provided text. While the results are promising, this analysis combines data from different studies. It is important to remember that every person reacts differently to medicine. Doctors will need to weigh these results against individual patient needs before making decisions.